Table 1 Clinicopathological variables and expression of miR-301a in the study cohort.
From: Elevated miR-301a expression indicates a poor prognosis for breast cancer patients
Variables | Patient Number(%) | miR-301a expression | Pa Value | |
|---|---|---|---|---|
| Â | Negative N (%) | Positive N (%) | ||
Total | 380 | 239(62.9) | 141(37.1) | Â |
Age(years) | 380 | 51.0 ± 9.9 | 52.7 ± 9.8 | 0.914 |
Menopausal status | Â | Â | Â | 0.014 |
  Pre | 193(50.8) | 133(35.0) | 60(15.8) |  |
  Post | 187(49.2) | 106(27.9) | 81(21.3) |  |
TNM stage | Â | Â | Â | 0.079 |
  I | 108(28.4) | 63(16.6) | 45(11.8) |  |
  II | 190(50.0) | 130(34.2) | 60(15.8) |  |
  III | 82(21.6) | 46(12.1) | 36(9.5) |  |
Grade | Â | Â | Â | 0.189 |
  1 or 2 | 284(74.7) | 184(48.4) | 100(26.3) |  |
  3 | 96(25.3) | 55(14.5) | 41(10.8) |  |
Tumour size | Â | Â | Â | 0.081 |
  ≤2 cm | 179(47.1) | 112(29.5) | 67(17.6) |  |
  >2, ≤5 cm | 183(48.2) | 120(31.6) | 63(16.6) |  |
  >5 cm | 18(4.7) | 7(1.8) | 11(2.9) |  |
Lymph node status | Â | Â | Â | 0.950 |
  Negative | 211(55.5) | 133(35.0) | 78(20.5) |  |
  Positive | 169(44.5) | 99(26.1) | 63(16.6) |  |
ER status | Â | Â | Â | 0.169 |
  Negative | 209(55.0) | 125(32.9) | 84(22.1) |  |
  Positive | 171(45.0) | 114(30.0) | 57(15.0) |  |
PR status | Â | Â | Â | 0.063 |
  Negative | 247(65.0) | 147(38.7) | 100(26.3) |  |
  Positive | 133(35.0) | 92(24.2) | 41(10.8) |  |
HER-2 status | Â | Â | Â | 0.911 |
  Negative | 217(57.1) | 137(36.1) | 80(21.1) |  |
  Positive | 163(42.9) | 102(26.8) | 61(16.1) |  |
Molecular subtypeb | Â | Â | Â | 0.159 |
  Luminal like | 176(46.3) | 119(31.3) | 57(15.0) |  |
HER-2 overexpression | 74(19.5) | 46(12.1) | 28(7.4) | Â |
  Triple negative | 130(34.2) | 74(19.5) | 56(14.7) |  |
